Drug Trial Radar · NCT05358379
A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
330
Planned (sponsor's estimate)
Start
Apr 14, 2022
Primary completion
Nov 2028
Study completion May 2029
Sponsor
- Lead sponsor
- Tethra Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- May 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.
Conditions
- Solid Tumor, Adult Lymphoma
Interventions
THT140Drug
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated doseTime frame: 6 months
- Overall Response Rate (ORR)Time frame: 18 months
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center/ University of Washington
Seattle, Washington · Recruiting
Seoul National University Hospital
Seoul, South Korea · Not yet recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.